Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal cancers
Abstract Synthetic lethal interactions (SLIs) can provide a therapeutic index, as illustrated by PARP inhibition of BRCA-deficient cancers1–4. Whereas additional SLIs based on genomic alterations in cancer have been identified5–19, we set out to explore the SLI space as a function of differential RNA expression profiles in cancer and normal tissue. By unbiased computational analyses of publicly available functional genomic and gene expression resources we uncovered a cancer-specific SLI between the paralogs cytidine diphosphate synthase 1 (CDS1) and CDS2. The essentiality of CDS2 for cell survival is observed for mesenchymal-like cancers, which express low levels of CDS1. We confirm the CDS1-2 SLI in a panel of cultured cancer cell lines and in tumor-bearing mice. Mechanistically, the CDS1-2 SLI is accompanied by disruption of lipid homeostasis including extensive accumulation of cholesterol esters and triglycerides, and induction of apoptotic cell death. Genome-wide CRISPR-Cas9 knockout screens in a panel of CDS1-negative cancer cell lines failed to identify a common escape mechanism of death caused by CDS2 ablation, indicating the robustness of the SLI. Our findings reveal that CDS2 may serve as a pharmacologically tractable target in mesenchymal cancers, meriting therapeutic exploration..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
ResearchSquare.com - (2023) vom: 21. Dez. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Arnoldus, Tim [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.21203/rs.3.rs-3626915/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA041798597 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA041798597 | ||
| 003 | DE-627 | ||
| 005 | 20231222131054.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231208s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-3626915/v1 |2 doi | |
| 035 | |a (DE-627)XRA041798597 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-3626915/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Arnoldus, Tim |e verfasserin |0 (orcid)0009-0005-2104-4832 |4 aut | |
| 245 | 1 | 0 | |a Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal cancers |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Synthetic lethal interactions (SLIs) can provide a therapeutic index, as illustrated by PARP inhibition of BRCA-deficient cancers1–4. Whereas additional SLIs based on genomic alterations in cancer have been identified5–19, we set out to explore the SLI space as a function of differential RNA expression profiles in cancer and normal tissue. By unbiased computational analyses of publicly available functional genomic and gene expression resources we uncovered a cancer-specific SLI between the paralogs cytidine diphosphate synthase 1 (CDS1) and CDS2. The essentiality of CDS2 for cell survival is observed for mesenchymal-like cancers, which express low levels of CDS1. We confirm the CDS1-2 SLI in a panel of cultured cancer cell lines and in tumor-bearing mice. Mechanistically, the CDS1-2 SLI is accompanied by disruption of lipid homeostasis including extensive accumulation of cholesterol esters and triglycerides, and induction of apoptotic cell death. Genome-wide CRISPR-Cas9 knockout screens in a panel of CDS1-negative cancer cell lines failed to identify a common escape mechanism of death caused by CDS2 ablation, indicating the robustness of the SLI. Our findings reveal that CDS2 may serve as a pharmacologically tractable target in mesenchymal cancers, meriting therapeutic exploration. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Vliet, Alex van |4 aut | |
| 700 | 1 | |a de Groot, Adriaan |4 aut | |
| 700 | 1 | |a Blomberg, Niek |4 aut | |
| 700 | 1 | |a Bleijerveld, Onno |0 (orcid)0000-0002-9395-2347 |4 aut | |
| 700 | 1 | |a Veen, Susan van Hal-van |4 aut | |
| 700 | 1 | |a Grootemaat, Anita |4 aut | |
| 700 | 1 | |a Harkes, Rolf |4 aut | |
| 700 | 1 | |a Wel, Nicole van der |4 aut | |
| 700 | 1 | |a Altelaar, Maarten |0 (orcid)0000-0001-5093-5945 |4 aut | |
| 700 | 1 | |a Giera, Martin |0 (orcid)0000-0003-1684-1894 |4 aut | |
| 700 | 1 | |a Peeper, Daniel |0 (orcid)0000-0003-1293-3177 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2023) vom: 21. Dez. |
| 773 | 1 | 8 | |g year:2023 |g day:21 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-3626915/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 21 |c 12 | ||